Abstract
Migraine headache is commonly treated with triptans (serotonin-receptor agonists), but, because these agents are associated with side effects (such as chest discomfort, dizziness, and throat tightness), they are poorly tolerated by some patients and contraindicated in those with cardiovascular disease. Telcagepant is a new calcitonin gene-related peptide antagonist that lacks the vasoconstrictor effects of triptans. In a randomized, controlled, double-blind, parallel-treatment trial funded by the …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
